Total Payments
$6,899
2024 Payments
$1,624
Companies
15
Transactions
683
Medicare Patients
6,154
Medicare Billing
$2.7M
Payment Breakdown by Category
Food & Beverage$6,650 (96.4%)
Education$248.48 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,650 | 677 | 96.4% |
| Education | $248.48 | 6 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,540 | 186 | $0 (2024) |
| Amgen Inc. | $1,629 | 210 | $0 (2024) |
| PFIZER INC. | $908.73 | 172 | $0 (2022) |
| UCB, Inc. | $611.88 | 36 | $0 (2024) |
| Lilly USA, LLC | $404.76 | 43 | $0 (2021) |
| Janssen Biotech, Inc. | $291.97 | 14 | $0 (2024) |
| GENZYME CORPORATION | $237.53 | 10 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $75.41 | 4 | $0 (2024) |
| Genentech USA, Inc. | $69.99 | 1 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $45.88 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,624 | 100 | ABBVIE INC. ($724.60) |
| 2023 | $966.45 | 69 | AbbVie Inc. ($690.17) |
| 2022 | $1,170 | 85 | ABBVIE INC. ($580.54) |
| 2021 | $808.62 | 71 | AbbVie Inc. ($226.85) |
| 2020 | $649.15 | 65 | Amgen Inc. ($238.64) |
| 2019 | $772.96 | 132 | PFIZER INC. ($248.89) |
| 2018 | $530.42 | 93 | Amgen Inc. ($206.29) |
| 2017 | $376.65 | 68 | Amgen Inc. ($186.60) |
All Payment Transactions
683 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $4.40 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: Inflammation | ||||||
| 11/14/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $28.60 | General |
| Category: Rheumatology | ||||||
| 11/08/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $9.15 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $9.75 | General |
| Category: Inflammation | ||||||
| 11/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $10.84 | General |
| Category: Rheumatology | ||||||
| 10/30/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: IMMUNOLOGY | ||||||
| 10/25/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Inflammation | ||||||
| 10/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $12.18 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.64 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: Inflammation | ||||||
| 09/17/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: Immunology | ||||||
| 09/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: IMMUNOLOGY | ||||||
| 09/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $3.42 | General |
| Category: IMMUNOLOGY | ||||||
| 09/12/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $30.36 | General |
| Category: Rheumatology | ||||||
| 09/11/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $9.01 | General |
| Category: Immunology | ||||||
| 09/06/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $4.50 | General |
| Category: Inflammation | ||||||
| 08/28/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $32.88 | General |
| Category: Immunology | ||||||
| 08/27/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $11.28 | General |
| Category: IMMUNOLOGY | ||||||
| 08/27/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $11.21 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,461 | 108,549 | $1.6M | $707,459 |
| 2022 | 12 | 1,392 | 73,322 | $1.2M | $553,601 |
| 2021 | 13 | 1,585 | 94,909 | $1.4M | $758,561 |
| 2020 | 14 | 1,716 | 76,928 | $1.2M | $684,819 |
Total Patients
6,154
Total Services
353,708
Medicare Billing
$2.7M
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 30 | 98,000 | $955,500 | $383,968 | 40.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 72 | 7,560 | $219,240 | $139,907 | 63.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 467 | 1,008 | $146,160 | $68,286 | 46.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 263 | 445 | $77,875 | $39,492 | 50.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 30 | 490 | $73,500 | $28,495 | 38.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 241 | 390 | $58,500 | $24,805 | 42.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 80 | 80 | $18,000 | $7,839 | 43.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 17 | 94 | $35,250 | $4,592 | 13.0% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 87 | 102 | $7,650 | $4,417 | 57.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 90 | 181 | $10,860 | $2,009 | 18.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $4,640 | $1,953 | 42.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 22 | 29 | $6,235 | $1,452 | 23.3% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 11 | 15 | $1,200 | $137.23 | 11.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 35 | 139 | $2,780 | $107.06 | 3.9% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 19 | 63,600 | $620,100 | $285,698 | 46.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 69 | 7,200 | $208,800 | $123,063 | 58.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 417 | 762 | $110,495 | $51,344 | 46.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 279 | 511 | $89,400 | $46,663 | 52.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 250 | 402 | $60,300 | $24,169 | 40.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 69 | 69 | $15,525 | $6,410 | 41.3% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 102 | 111 | $8,325 | $4,633 | 55.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 95 | 411 | $24,660 | $4,488 | 18.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 16 | 58 | $8,700 | $3,696 | 42.5% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 27 | 35 | $7,525 | $1,809 | 24.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $3,770 | $1,497 | 39.7% |
About Dr. Christopher D'arcy, M.D
Dr. Christopher D'arcy, M.D is a Rheumatology healthcare provider based in Westerly, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073560330.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher D'arcy, M.D has received a total of $6,899 in payments from pharmaceutical and medical device companies, with $1,624 received in 2024. These payments were reported across 683 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($6,650).
As a Medicare-enrolled provider, D'arcy has provided services to 6,154 Medicare beneficiaries, totaling 353,708 services with total Medicare billing of $2.7M. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Westerly, RI
- Active Since 05/30/2006
- Last Updated 09/19/2013
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1073560330
Products in Payments
- RINVOQ (Biological) $1,837
- Enbrel (Biological) $1,553
- XELJANZ (Drug) $758.31
- Cimzia (Drug) $577.43
- TALTZ (Drug) $353.92
- SKYRIZI (Biological) $326.57
- KEVZARA (Biological) $237.53
- TREMFYA (Drug) $210.27
- Humira (Biological) $160.42
- LYRICA (Drug) $112.48
- RINVOQ (Drug) $94.94
- ORENCIA (Biological) $75.41
- Rituxan (Biological) $69.99
- REMICADE (Biological) $68.47
- HUMIRA (Biological) $49.81
- Rinvoq (Biological) $46.58
- INFLECTRA (Biological) $37.94
- Bimzelx (Biological) $34.45
- OLUMIANT (Drug) $32.30
- CYLTEZO (Biological) $26.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.